摘要
比托哌汀为一种新型非典型抗精神病药物,为甘氨酸转运体(GlyT1)抑制剂,通过抑制甘氨酸的再摄取从而增加作为谷氨酸受体N-甲基-D-天冬氨酸(NMDA)受体激动剂的甘氨酸表达。与目前其他非典型抗精神病药物相比,该药对精神分裂症患者的阴性症状有明显的疗效,且对认知功能也有一定的改善。目前正处于临床Ⅲ期试验,现有资料提示该药有较好的有效性和安全性,但仍需要长期使用的资料积累。
Bitopertin as a new atypical antipsychotic agent is a glycine transporter type 1 （GlyT1） inhibitor that increases levels of the neurotransmitter glycine by inhibiting its reuptake. Glycine acts as a coagonist along with glutamate at N-methyl- D- aspartate （NMDA） receptors. Compared with other atypical antipsychotics, bitopertin can not only produce a significant effect on the negative symptoms of schizophrenia, but also improve cognitive impairment. It is in phase m clinical trials, and the present clinical data show that it is effective and safe, but further studies for long term observation are necessary.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2014年第7期485-489,共5页
Chinese Journal of New Drugs and Clinical Remedies
基金
"重大新药创制"科技重大专项--精神药物新药临床评价研究技术平台(2008ZX09312-003)
